Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This study is determining whether the addition of cyclophosphamide to pomalidomide and dexamethasone improves progression free survival in patients with relapsed refractory myeloma (RRMM) compare to pomalidomide and dexamethasone alone. Patients will be randomised on a 1:1 basis to receive CPD or Pd. Treatment will be continued until disease progression or unacceptable toxicity.
Epistemonikos ID: 373d90886c2ccbfa0e0c0698b5adbd62cf99c8bd
First added on: May 12, 2024